GlaxoSmithKline Historical Balance Sheet

GSK Stock

USD 38.97 0.45 1.17%

Trend analysis of GlaxoSmithKline PLC ADR balance sheet accounts such as Other Current Liabilities of 15.9 B or Total Current Liabilities of 11.5 B provides information on GlaxoSmithKline PLC's total assets, liabilities, and equity, which is the actual value of GlaxoSmithKline PLC ADR to its prevalent stockholders. By breaking down trends over time using GlaxoSmithKline PLC balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Black Monday

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining GlaxoSmithKline PLC ADR latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether GlaxoSmithKline PLC ADR is a good buy for the upcoming year.

GlaxoSmithKline PLC Inventory

3.05 Billion

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

About GlaxoSmithKline Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of GlaxoSmithKline PLC ADR at a specified time, usually calculated after every quarter, six months, or one year. GlaxoSmithKline PLC Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of GlaxoSmithKline PLC and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which GlaxoSmithKline currently owns. An asset can also be divided into two categories, current and non-current.

GlaxoSmithKline PLC Balance Sheet Chart

At this time, GlaxoSmithKline PLC's Property Plant And Equipment Gross is quite stable compared to the past year. Retained Earnings is expected to rise to about 8.2 B this year, although the value of Total Current Liabilities will most likely fall to about 11.5 B.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Accumulated Amortization

Add Fundamental

Total Assets

Total assets refers to the total amount of GlaxoSmithKline PLC assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in GlaxoSmithKline PLC ADR books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on GlaxoSmithKline PLC balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of GlaxoSmithKline PLC ADR are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accumulated Amortization

The cumulative amount of amortization expense charged against intangible assets, like patents and copyrights, over time.

Most accounts from GlaxoSmithKline PLC's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into GlaxoSmithKline PLC ADR current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	21.0B	18.0B	17.0B	11.2B
Total Assets	60.1B	59.0B	59.5B	33.6B

Short Long Term Debt Total Total Assets

GlaxoSmithKline PLC balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Capital Stock	Short Term Debt	Common Stock	Retained Earnings	Intangible Assets
Total Assets		0.9	0.21	0.89	0.5	0.89	0.89	0.3	0.59	0.99	0.37	0.56	0.24	0.76	0.05	0.94	0.95	0.5	0.97	0.33	0.91	0.7	0.68	0.7	0.13	0.93
Short Long Term Debt Total	0.9		0.04	0.8	0.38	0.87	0.98	0.41	0.64	0.89	0.33	0.56	0.0	0.62	0.0	0.9	0.87	0.57	0.9	0.17	0.86	0.69	0.87	0.69	0.0	0.82
Other Current Liab	0.21	0.04		0.11	0.8	0.13	0.01	-0.64	0.13	0.16	0.31	0.42	0.81	0.56	0.32	0.02	0.19	-0.17	0.06	0.59	0.35	0.38	-0.25	0.38	0.71	0.1
Total Current Liabilities	0.89	0.8	0.11		0.33	0.89	0.81	0.48	0.42	0.87	0.5	0.48	0.2	0.7	0.17	0.81	0.94	0.58	0.93	0.39	0.86	0.72	0.68	0.72	-0.03	0.76
Total Stockholder Equity	0.5	0.38	0.8	0.33		0.28	0.39	-0.48	0.14	0.49	0.23	0.34	0.79	0.79	0.19	0.27	0.38	-0.15	0.31	0.61	0.48	0.38	0.19	0.38	0.89	0.48
Property Plant And Equipment Net	0.89	0.87	0.13	0.89	0.28		0.82	0.53	0.71	0.84	0.34	0.63	0.01	0.58	-0.03	0.9	0.96	0.78	0.94	0.41	0.93	0.9	0.69	0.9	-0.17	0.73
Net Debt	0.89	0.98	0.01	0.81	0.39	0.82		0.38	0.49	0.88	0.36	0.46	0.06	0.65	0.06	0.87	0.85	0.52	0.89	0.19	0.81	0.61	0.9	0.61	0.06	0.82
Accounts Payable	0.3	0.41	-0.64	0.48	-0.48	0.53	0.38		0.34	0.3	-0.02	0.06	-0.63	-0.17	-0.33	0.44	0.41	0.66	0.47	-0.07	0.28	0.34	0.51	0.34	-0.72	0.29
Cash	0.59	0.64	0.13	0.42	0.14	0.71	0.49	0.34		0.54	0.09	0.73	-0.25	0.24	-0.26	0.67	0.6	0.53	0.6	0.02	0.7	0.71	0.37	0.71	-0.21	0.48
Non Current Assets Total	0.99	0.89	0.16	0.87	0.49	0.84	0.88	0.3	0.54		0.32	0.47	0.24	0.74	0.0	0.93	0.92	0.45	0.95	0.29	0.85	0.63	0.67	0.63	0.15	0.96
Non Currrent Assets Other	0.37	0.33	0.31	0.5	0.23	0.34	0.36	-0.02	0.09	0.32		0.58	0.36	0.49	0.71	0.32	0.39	0.14	0.41	0.11	0.52	0.34	0.31	0.34	0.08	0.21
Cash And Short Term Investments	0.56	0.56	0.42	0.48	0.34	0.63	0.46	0.06	0.73	0.47	0.58		0.12	0.52	0.44	0.57	0.57	0.4	0.56	0.16	0.81	0.66	0.34	0.66	0.02	0.35
Common Stock Total Equity	0.24	0.0	0.81	0.2	0.79	0.01	0.06	-0.63	-0.25	0.24	0.36	0.12		0.64	0.39	0.02	0.17	-0.35	0.1	0.62	0.21	0.11	-0.16	0.11	0.79	0.24
Common Stock Shares Outstanding	0.76	0.62	0.56	0.7	0.79	0.58	0.65	-0.17	0.24	0.74	0.49	0.52	0.64		0.43	0.58	0.72	0.22	0.66	0.55	0.76	0.55	0.44	0.55	0.58	0.64
Short Term Investments	0.05	0.0	0.32	0.17	0.19	-0.03	0.06	-0.33	-0.26	0.0	0.71	0.44	0.39	0.43		-0.03	0.07	-0.08	0.05	0.06	0.25	-0.03	0.02	-0.03	0.23	-0.11
Non Current Liabilities Total	0.94	0.9	0.02	0.81	0.27	0.9	0.87	0.44	0.67	0.93	0.32	0.57	0.02	0.58	-0.03		0.92	0.64	0.97	0.21	0.86	0.68	0.71	0.68	-0.13	0.88
Inventory	0.95	0.87	0.19	0.94	0.38	0.96	0.85	0.41	0.6	0.92	0.39	0.57	0.17	0.72	0.07	0.92		0.69	0.97	0.43	0.94	0.82	0.66	0.82	-0.02	0.8
Other Stockholder Equity	0.5	0.57	-0.17	0.58	-0.15	0.78	0.52	0.66	0.53	0.45	0.14	0.4	-0.35	0.22	-0.08	0.64	0.69		0.65	0.32	0.63	0.73	0.48	0.73	-0.52	0.31
Total Liab	0.97	0.9	0.06	0.93	0.31	0.94	0.89	0.47	0.6	0.95	0.41	0.56	0.1	0.66	0.05	0.97	0.97	0.65		0.3	0.91	0.73	0.73	0.73	-0.09	0.87
Property Plant And Equipment Gross	0.33	0.17	0.59	0.39	0.61	0.41	0.19	-0.07	0.02	0.29	0.11	0.16	0.62	0.55	0.06	0.21	0.43	0.32	0.3		0.41	0.58	0.08	0.58	0.4	0.22
Total Current Assets	0.91	0.86	0.35	0.86	0.48	0.93	0.81	0.28	0.7	0.85	0.52	0.81	0.21	0.76	0.25	0.86	0.94	0.63	0.91	0.41		0.86	0.64	0.86	0.07	0.71
Capital Stock	0.7	0.69	0.38	0.72	0.38	0.9	0.61	0.34	0.71	0.63	0.34	0.66	0.11	0.55	-0.03	0.68	0.82	0.73	0.73	0.58	0.86		0.49	1.0	-0.04	0.47
Short Term Debt	0.68	0.87	-0.25	0.68	0.19	0.69	0.9	0.51	0.37	0.67	0.31	0.34	-0.16	0.44	0.02	0.71	0.66	0.48	0.73	0.08	0.64	0.49		0.49	-0.08	0.64
Common Stock	0.7	0.69	0.38	0.72	0.38	0.9	0.61	0.34	0.71	0.63	0.34	0.66	0.11	0.55	-0.03	0.68	0.82	0.73	0.73	0.58	0.86	1.0	0.49		-0.04	0.47
Retained Earnings	0.13	0.0	0.71	-0.03	0.89	-0.17	0.06	-0.72	-0.21	0.15	0.08	0.02	0.79	0.58	0.23	-0.13	-0.02	-0.52	-0.09	0.4	0.07	-0.04	-0.08	-0.04		0.19
Intangible Assets	0.93	0.82	0.1	0.76	0.48	0.73	0.82	0.29	0.48	0.96	0.21	0.35	0.24	0.64	-0.11	0.88	0.8	0.31	0.87	0.22	0.71	0.47	0.64	0.47	0.19

Click cells to compare fundamentals

GlaxoSmithKline PLC Account Relationship Matchups

GlaxoSmithKline PLC balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	80.4B	79.1B	60.1B	59.0B	59.5B	33.6B
Short Long Term Debt Total	27.2B	24.2B	21.0B	18.0B	17.0B	11.2B
Other Current Liab	13.2B	14.7B	14.2B	13.8B	15.2B	15.9B
Total Current Liabilities	22.1B	23.7B	22.8B	21.1B	21.7B	11.5B
Total Stockholder Equity	14.6B	15.1B	10.6B	13.3B	13.7B	14.4B
Property Plant And Equipment Net	11.0B	10.7B	9.6B	10.0B	10.1B	7.3B
Net Debt	20.9B	19.9B	17.3B	15.3B	13.3B	8.4B
Accounts Payable	4.4B	4.5B	3.9B	3.7B	3.5B	5.1B
Cash	6.3B	4.3B	3.7B	2.7B	3.7B	2.8B
Non Current Assets Total	60.2B	60.4B	39.4B	40.4B	42.5B	21.5B
Non Currrent Assets Other	1.1B	1.8B	5.3B	634M	1.9B	1.1B
Cash And Short Term Investments	6.4B	4.3B	7.9B	5.0B	3.7B	4.0B
Common Stock Shares Outstanding	4.0B	3.2B	4.1B	4.1B	4.1B	2.2B
Liabilities And Stockholders Equity	80.4B	79.1B	60.1B	59.0B	59.5B	33.6B
Non Current Liabilities Total	37.5B	34.1B	27.2B	25.1B	24.7B	14.6B
Inventory	6.0B	5.8B	5.1B	5.5B	5.7B	3.1B
Other Stockholder Equity	3.1B	3.3B	3.7B	4.8B	4.5B	2.9B
Total Liab	59.6B	57.8B	50.1B	46.2B	46.4B	26.1B
Property Plant And Equipment Gross	11.0B	10.7B	9.6B	20.2B	20.6B	21.6B
Total Current Assets	20.2B	18.7B	20.8B	18.6B	17.0B	12.1B
Short Term Debt	3.7B	3.6B	4.0B	2.8B	2.3B	2.2B
Retained Earnings	6.8B	7.9B	4.4B	7.2B	7.8B	8.2B
Accumulated Other Comprehensive Income	1.6B	642M	(48M)	1.6B	1.8B	1.9B
Intangible Assets	29.8B	30.1B	14.3B	14.8B	15.5B	11.6B
Other Liab	13.7B	14.1B	13.5B	10.2B	11.7B	14.2B
Long Term Debt	23.4B	20.6B	17.0B	14.2B	13.7B	17.4B
Good Will	10.6B	10.6B	7.0B	6.8B	7.0B	5.4B
Other Current Assets	1.9B	1.7B	1.4B	1.6B	7.6B	8.0B
Property Plant Equipment	11.3B	11.0B	10.7B	9.6B	8.7B	9.7B
Current Deferred Revenue	1.8B	1.6B	299M	222M	255.3M	268.1M
Other Assets	5.1B	5.3B	6.9B	6.9B	7.9B	5.4B
Net Receivables	5.5B	6.2B	5.5B	5.9B	5.6B	6.1B
Net Tangible Assets	(30.1B)	(25.8B)	(25.6B)	(10.8B)	(12.4B)	(13.0B)
Short Long Term Debt	3.5B	3.4B	3.8B	2.7B	2.2B	4.1B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:

How To Invest In GlaxoSmithKline

Details

Is GlaxoSmithKline Stock a good investment?

Details

What is GlaxoSmithKline PLC's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.173

Dividend Share

0.61

Earnings Share

1.61

Revenue Per Share

15.392

Quarterly Revenue Growth

0.008

The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

GlaxoSmithKline Historical Balance Sheet

GlaxoSmithKline PLC Inventory

3.05 Billion

About GlaxoSmithKline Balance Sheet Analysis

GlaxoSmithKline PLC Balance Sheet Chart

Total Assets

Total Current Liabilities

Accumulated Amortization

GlaxoSmithKline PLC balance sheet Correlations

GlaxoSmithKline PLC Account Relationship Matchups

High Positive Relationship

High Negative Relationship

GlaxoSmithKline PLC balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Capital Stock
Non Current Assets Total	+ 0.99	Total Assets
Net Debt	+ 0.98	Short Long Term Debt Total
Total Liab	+ 0.97	Total Assets
Total Liab	+ 0.97	Non Current Liabilities Total
Total Liab	+ 0.97	Inventory

Retained Earnings	- 0.72	Accounts Payable
Accounts Payable	- 0.64	Other Current Liab
Common Stock Total Equity	- 0.63	Accounts Payable
Retained Earnings	- 0.52	Other Stockholder Equity
Accounts Payable	- 0.48	Total Stockholder Equity
Other Stockholder Equity	- 0.35	Common Stock Total Equity